2020
DOI: 10.1016/j.ejmech.2019.111865
|View full text |Cite
|
Sign up to set email alerts
|

Isoquinoline-based biaryls as a robust scaffold for microtubule inhibitors

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
8
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
8
1

Relationship

4
5

Authors

Journals

citations
Cited by 12 publications
(8 citation statements)
references
References 37 publications
0
8
0
Order By: Relevance
“…We aimed to formulate water-soluble SBTub prodrugs by phenol phosphorylationan approach that has been successful for other colchicinoid inhibitors (including clinically advanced CA4P, BNC105P, etc). 37 We had initially produced SBTub3P, the phosphate prodrug of previous lead compound SBTub3, however, its aqueous solubility was only moderate (<2 mg/mL) potentially due to aggregate formation by π-stacking of the planar compound. We synthesized SBTubA4P hoping that the out-of-plane central methoxy group would reduce π-stacking, which combined with the hydrophilicity of the three extra methoxy groups would give better solubility, as we have seen in other contexts.…”
Section: Resultsmentioning
confidence: 99%
See 1 more Smart Citation
“…We aimed to formulate water-soluble SBTub prodrugs by phenol phosphorylationan approach that has been successful for other colchicinoid inhibitors (including clinically advanced CA4P, BNC105P, etc). 37 We had initially produced SBTub3P, the phosphate prodrug of previous lead compound SBTub3, however, its aqueous solubility was only moderate (<2 mg/mL) potentially due to aggregate formation by π-stacking of the planar compound. We synthesized SBTubA4P hoping that the out-of-plane central methoxy group would reduce π-stacking, which combined with the hydrophilicity of the three extra methoxy groups would give better solubility, as we have seen in other contexts.…”
Section: Resultsmentioning
confidence: 99%
“…Our second priority was to develop soluble SBTubs for in vivo use in multiorgan animal models, which do not easily tolerate even low amounts of organic cosolvents, and which may require temperatures below those of typical 2D cell cultures (e.g., <30 °C for zebrafish). We aimed to formulate water-soluble SBTub prodrugs by phenol phosphorylationan approach that has been successful for other colchicinoid inhibitors (including clinically advanced CA4P , BNC105P , etc) . We had initially produced SBTub3P , the phosphate prodrug of previous lead compound SBTub3 , however, its aqueous solubility was only moderate (<2 mg/mL) potentially due to aggregate formation by π-stacking of the planar compound.…”
Section: Resultsmentioning
confidence: 99%
“…In continuation of our recent work on the chemistry and pharmacology of benzylisoquinolines and related compounds [6][7][8][9][10][11][12][13][14] we investigated truncated analogues of the bisbenzylisoquino-line alkaloid tetrandrine as blockers of the calcium channel twopore channel 2 (TPC2), and identified 1-benzyl-1,2,3,4-tetrahydroisoquinolines bearing phenoxy and benzyloxy substituents (SG-005, SG-094; for structures of bioactive compounds mentioned in this text, see Figure S1 in Supporting Information File 1) on both aromatic rings as potent blockers with promising antitumor activity [15]. In this work we took advantage of the hitherto less explored N-acyl-Pictet-Spengler reaction and related chemistry based on the seminal work of Speckamp [16], where an N-acyl residue at the arylethylamine building block leads to enhanced cyclization rates due to the acid-mediated formation of highly electrophilic N-acyliminium intermediates [17].…”
Section: Introductionmentioning
confidence: 92%
“…Our second priority was to develop soluble SBTubs for in vivo use in multiorgan animal models, which do not easily tolerate even low amounts of organic cosolvents. We aimed to formulate water-soluble SBTub prodrugs by phenol phosphorylation -an approach that has been generally successful for colchicinoid inhibitors (including clinically-advanced CA4P, BNC105P etc) 34 . We had initially produced SBTub3P, the phosphate prodrug of previous lead compound SBTub3, however its aqueous solubility was only moderate (<2 mg/mL) potentially due to aggregate formation by π-stacking of the planar compound.…”
Section: Cellular Structure-activity Optimisation Of Sbtubsmentioning
confidence: 99%